Jim Simons Spruce Biosciences, Inc. Transaction History

Renaissance Technologies LLC

$63.6 Billion
Q1 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Spruce Biosciences, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 271,000 shares of SPRB stock, worth $140,920. This represents 0.0% of its overall portfolio holdings.

Number of Shares

271,000

Previous 185,100 46.41%

Holding current value

$140,920

Previous $542,000 60.7%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$0.7 - $5.49 $60,129 - $471,591	85,900 Added 46.41%	271,000 $213,000
Q4 2023 Feb 13, 2024	SELL	$1.04 - $2.93 $23,583 - $66,440	-22,676 Reduced 10.91%	185,100 $542,000
Q3 2023 Nov 14, 2023	SELL	$2.04 - $2.54 $63,898 - $79,560	-31,323 Reduced 13.1%	207,776 $470,000
Q2 2023 Aug 11, 2023	BUY	$1.92 - $2.6 $151,678 - $205,397	78,999 Added 49.34%	239,099 $514,000
Q1 2023 May 12, 2023	BUY	$1.15 - $3.17 $24,935 - $68,735	21,683 Added 15.66%	160,100 $354,000

Q4 2022 Feb 13, 2023	SELL	$0.99 - $1.19 $4,636 - $5,572	-4,683 Reduced 3.27%	138,417 $152,000
Q3 2022 Nov 14, 2022	SELL	$1.37 - $2.19 $11,371 - $18,177	-8,300 Reduced 5.48%	143,100 $196,000
Q2 2022 Aug 12, 2022	BUY	$1.28 - $2.23 $50,816 - $88,531	39,700 Added 35.54%	151,400 $263,000
Q1 2022 May 13, 2022	BUY	$1.85 - $4.59 $133,015 - $330,021	71,900 Added 180.65%	111,700 $225,000
Q4 2021 Feb 11, 2022	BUY	$2.33 - $5.74 $13,514 - $33,292	5,800 Added 17.06%	39,800 $178,000
Q3 2021 Nov 12, 2021	BUY	$6.01 - $11.26 $204,340 - $382,840	34,000 New	34,000 $204,000

Others Institutions Holding SPRB

# of Institutions

Shares Held

18.3M

Call Options Held

49K

Put Options Held

48.1K

View Full List

About SPRUCE BIOSCIENCES, INC.

Ticker SPRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,560,200
Market Cap $12.3M
Description
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which i...

More about SPRB

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account